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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPER1Pathogenesis of Acute Coronary SyndromesFilippo Crea, Giovanna Liuzzo
Experimental models of atherogenesis have helped to outline the molecular mechanisms of
plaque growth; however, the transition from coronary stability to instability is less well
understood. A better understanding of the causes of coronary instability might allow the
identification of new therapeutic targets. In this review, Crea and Luizzo propose a pathogenetic
classification of acute coronary syndrome which might help in the search of new diagnostic
algorithms and therapeutic targets.STATE-OF-THE-ART PAPER12Hypertension and Vascular Dynamics in Men and Women With Metabolic SyndromeMichel E Safar, Beverley Balkau, Céline Lange, Athanase D. Protogerou, Sébastien Czernichow,
Jacques Blacher, Bernard I. Levy, Harold Smulyan
Safer and colleagues sought to determine the possible contributions of aortic stiffness, wave
reflections and pulse pressure (PP) amplification to the mechanisms of cardiovascular
complications observed in subjects with hypertension, diabetes mellitus or their combination.
The effects of metabolic syndrome (MetS) on brachial PP, central PP, PP amplification,
aortic stiffness and wave reflections were studied by comparing MetS subjects to those with
hypertension but not MetS. MetS was associated with increased aortic stiffness, reduced wave
reflections and increased PP amplification. This pulsatile hemodynamic abnormality
contributes independently to an increased age- and six-mediated cardiovascular risk.VIEWPOINT20The Subcutaneous ICD: Should Patients Want One?Robert G. Hauser
The subcutaneous implantable cardioverter-defibrillator is a novel device that does not require
insertion of a transvenous lead; rather, it delivers 80 Joule transthoracic shocks via a subcutaneous
pulse generator implanted in the left lateral chest and a subcutaneous left parasternal lead-
electrode. It recently received approval by an Food and Drug Administration panel based on the
results of a 180-day prospective, single-arm, 330 patient multicenter study, where the device met
the study endpoint of successful detection and termination of induced ventricular fibrillation (VF)
and data from previous studies and registries. Hauser, argues that this device has not yet been
adequately tested for spontaneous VF, nor for sustained periods in ambulatory patients. The device
is also limited in that it does not provide either antitachycardia or bradycardia pacing.(continued on page A-23)
JANUARY 8, 2013 (continued) A-23CLINICAL RESEARCH INTERVENTIONAL CARDIOLOGY23Risk of Periprocedural MI Predicted by Fibrinogen Not Platelet ReactivityLawrence Ang, Khalid Bin Thani, Manjusha Ilapakurti, Michael S. Lee, Vachaspathi Palakodeti,
Ehtisham Mahmud
Ang and colleagues studied the links between serum fibrinogen and residual platelet reactivity
after clopidogrel pretreatment on ischemic events after elective percutaneous coronary
intervention (PCI). Serum fibrinogen and platelet function using the VerifyNow P2Y12 assay
were measured prior to PCI in nearly 200 patients undergoing elective PCI who were pre-
treated with clopidogrel. The incidence of troponin-defined periprocedural myocardial
infarction (PPMI) was 14% and associated with elevated fibrinogen, higher age, and elevated
platelet count. Platelet reactivity measurements were not associated with PPMI. In
clopidogrel pre-treated patients undergoing elective PCI, fibrinogen appears to be more useful
than platelet reactivty for predicting PPMI.QUALITY AND OUTCOMES35Low Rates of Aldosterone Antagonists Post-AMI Despite Guideline RecommendationsAndrew N. Rassi, Matthew A. Cavender, Gregg C. Fonarow, Christopher P. Cannon, Adrian F. Hernandez,
Eric D. Peterson, W. Frank Peacock, Warren K. Laskey, Sylvia E. Rosas, Xin Zhao, Lee H. Schwamm,
Deepak L. Bhatt
Current guidelines recommend initiation of aldosterone antagonist therapy post-acute
myocardial infarction (AMI) for patients with an ejection fraction (EF) 40% and heart
failure or diabetes prior to hospital discharge, in the absence of contraindications. Rassi and
associates explored temporal trends in the use of aldosterone antagonist therapy among
eligible patients using data from the Get with the Guidelines-Coronary Artery Disease
national database. Among eligible patients, 9.1% were prescribed an aldosterone antagonist at
discharge. Aldosterone antagonist use varied from 0% to 40% among hospitals. From 2006 to
2009, the use of aldosterone antagonists increased from 6.0% to 13.4%. Although rates of
utilization of aldosterone antagonists are rising slightly over time, the vast majority of AMI
patients eligible for treatment fail to receive it at hospital discharge.
Editorial Comment: Wilbur Y. W. Lew, Anthony N. DeMaria, page 41(continued on page A-24)
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44lucose Intolerance and Decreased Mitochondrial Function in
Skeletal Muscle From Simvastatin-Treated PatientsSteen Larsen, Nis Stride, Martin Hey-Mogensen, Christina N. Hansen, Lia E. Bang, Henning Bundgaard,
Lars B. Nielsen, Jørn W. Helge, Flemming Dela
A prevalent side-effect of statin therapy is muscle pain, but the mechanisms remain unknown.
Larsen and colleagues studied the roles of glucose tolerance and skeletal muscle coenzyme
Q10 (Q10) content, mitochondrial density and mitochondrial oxidative phosphorylation
(OXPHOS) capacity as a possible underlying mechanism. Muscle biopsies were obtained in
patients chronically treated with simvastatin and compared to control subjects. Q10 content
was reduced, but mitochondrial content was similar. OXPHOS capacity was comparable
between groups when complex I and complex II linked substrates were used alone, but
simvastatin reduced maixmal OXPHOS capacity when complex III linked substrates were
used. These findings may explain the muscle pain and exercise intolerance that many patients
experience with statin treatment.HEART FAILURE
54ovel Predictors of Left Ventricular Reverse Remodeling
in Individuals With Recent-Onset Dilated CardiomyopathyMilos Kubanek, Marek Sramko, Jana Maluskova, Dana Kautznerova, Jiri Weichet, Petr Lupinek,
Jana Vrbska, Ivan Malek, Josef Kautzner
Kubanek and colleagues compared the utility of cardiac magnetic resonance imaging (CMRI),
cardiac biomarkers, and endomyocardial biopsy (EMB) results to predict left ventricular
reverse remodeling (LVRR) in individuals with recent-onset dilated cardiomyopathy (DCM).
LVRR occurred in approximately one-half of the patients. At baseline, a lower extent of late
gadolinium enhancement and a higher myocardial edema ratio measured by CMRI were
independent predictors of LVRR. At 3 months, BNP plasma level was the only independent
predictor of LVRR. These results show that both baseline CMRI and serial BNP testing are
better at predicting LVRR than EMB results, other biomarkers, or the conventional methods
of follow-up.
Editorial Comment: Matthias Friedrich, page 64(continued on page A-25)
JANUARY 8, 2013 (continued) A-253HEART RHYTHM DISORDERS66Reasons for Recurrent VT After Catheter Ablation of Post-Infarction VTMiki Yokokawa, Benoit Desjardins, Thomas Crawford, Eric Good, Fred Morady, Frank Bogun
Yokokawa and colleagues performed a retrospective review of 98 patients who underwent
catheter ablation for post-infarction ventricular tachycardia (VT). Electrograms from the
implantable cardioverter defibrillator (ICD) were analyzed and VTs were classified as clinical
or nonclinical. A total of 725 VTs were induced during the ablation procedure, and all VTs
were targeted for ablation. Immediately post-ablation, the clinical VT was not inducible in
any patient. During follow-up, one-third of patients had VT recurrence. This was a new VT
in 79% with the remainder having recurrence of a prior clinical VT. Patients with recurrent
VT had a larger scar area and for patients who underwent follow-up ablation procedure, the
new VT was found to involve critical areas near prior ablation lesions.Editorial Comment: Edward P. Gerstenfeld, page 74CARDIAC IMAGING
77D Echocardiographic Techniques Improve Reproducibility for
Sequential Assessment of Left Ventricular Ejection Fraction and VolumesPaaladinesh Thavendiranathan, Andrew D. Grant, Tomoko Negishi, Juan Carlos Plana, Zoran B. Popovic´,
Thomas H. Marwick
Thavendiranathan and colleagues sought to identify the echocardiographic method for left
ventricular ejection fraction (LVEF) and ventricular volume quantification with the lowest
variability. Breast cancer patients underwent LV assessment every 3 months for up to 5 time
points with a comprehensive echocardiogram consisting of 2D and 3D acquisitions with and
without contrast administration. All patients had stable LV function as measured by global
longitudinal strain at each examination. EF and volumes were measured using 2D-biplane
Simpson’s method, 2D-triplane, and 3D by 2 investigators. 3D had significantly lower
longitudinal variability for EF, EDV, and ESV than all the other methods. Further analysis
estimated that 3D had 6.0% variability compared to 10% for 2D methods. These results
suggest that 3D acquisitions reduce measurement variability.
Editorial Comment: Victor Mor-Avi, Roberto M. Lang, page 85(continued on page A-26)
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Ludovica Grasso, Carolina Di Somma, Pierluigi Mauri, Louise Benazzi, Anna Franzone,
Gloria Saccani Jotti, Marie-Louise Bang, Giovanni Esposito, Annamaria Colao, Gianluigi Condorelli,
Daniele Catalucci
MicroRNAs (miRs), which are small non-coding RNAs that negatively modulate the
translation of target mRNAs, are likely involved in many of the compensatory mechanisms in
the heart. Catalucci and associates sought to identify the proteins secreted by cardiomyocytes
(CM) that are targeted by the muscle-specific miR-1. Proteomic analysis of supernatants
from cultured CMs overexpressing miR-1 revealed downregulation of heart-type fatty acid-
binding protein-3 (FABP3) secretion. Further in vitro and in vivo analyses confirmed an
inverse relationship between miR-1 and serum FABP3 levels.VASCULAR DISEASE96Sex Differences in Arterial Stiffness and Ventricular-Arterial InteractionsThais Coutinho, Barry A. Borlaug, Patricia A. Pellikka, Stephen T. Turner, Iftikhar J. Kullo
Coutinho and colleagues sought to better understand how sex differences in ventricular and
arterial stiffness and ventricular-arterial coupling might contribute to the greater risk of heart
failure with preserved ejection fraction (HFpEF) in women. The hemodynamic (arterial) load
on the left ventricle was divided into steady (systemic vascular resistance) and pulsatile
components (total arterial compliance [TAC] and aortic characteristic impedance [Zc]).
Although mean arterial pressure did not differ between sexes, brachial and central pulse
pressure (PP) were significantly higher in women. Women also had attenuated PP
amplification lower TAC, consistent with greater vascular stiffness in women than in men.
These findings confirm the hypothesis that pulsatile hemodynamic load on the left ventricle is
significantly associated with diastolic dysfunction in women.
